Its role in the pathogenesis of GvHD has been extensively described: TNF-α is released in patients after conditioning regimens with chemotherapy and/or radiotherapy and during the active phase of acute GvHD, and it is believed to enhance CD8+ T cell mediated alloreactivity exacerbating immune destruction of GvHD target tissues (10, 29). Here, TNF is linked to graft versus host disease.